The Complete Perimenopause Guide

Many women don't walk into a doctor's office and say "I think I'm in perimenopause." They say something closer to "I don't feel like myself."

In a study of over 1,500 women in the US and Canada, 63.3% reported not feeling like themselves at least half the time over the previous three months (38). That feeling has a name in the research — "not feeling like myself," or NFLM — and in that study, the symptoms driving it were not the ones most people associate with menopause.

What Actually Drives That Feeling

In that study, the strongest predictors of not feeling like yourself were fatigue, feeling overwhelmed, and anxiety — not hot flashes. Fatigue correlated with NFLM at r=0.491 and feeling overwhelmed at r=0.463, while hot flashes came in at r=0.277 and vaginal dryness at r=0.205. Five symptom groups — anxiety and vigilance, fatigue and pain, brain fog, sexual symptoms, and volatile mood — together explained 41.8% of NFLM scores.

This matters because many women don't connect their fatigue, brain fog, or mood changes to perimenopause. There is anticipatory guidance for puberty. There is anticipatory guidance for pregnancy. Many women do not receive an equivalent kind of guidance for perimenopause — and so when the symptoms arrive, they often lack a framework for what is happening to them. They don't know that what they're experiencing has a physiological explanation.

What Perimenopause Actually Is

Perimenopause is the menopausal transition — a distinct physiological phase where ovarian function fluctuates, hormone levels become unpredictable, and menstrual patterns change before eventually stopping. It is not simply "early menopause." By 2030, over 1.2 billion women worldwide will be in menopause or postmenopause (120).

During this transition, fluctuating hormones affect multiple systems simultaneously, which is why symptoms span mood, sleep, cognition, and physical function rather than appearing in isolation. The Mood, Sleep & Cognition section explains how these pathways work.

Perimenopause also involves ongoing contraception considerations. Guidelines recommend contraception for 1 year after the final menstrual period for women over 50, and for 2 years for women under 50. This is one of several ways perimenopause involves its own management considerations, distinct from postmenopause.

Your Experience Depends on Who You Are

Symptom duration and severity vary across populations, and studies show important differences by race, ethnicity, stress exposure, and healthcare context. The commonly cited "average duration of 2-5 years" does not apply equally to everyone.

Across 41 low- and middle-income countries, the prevalence of hot flashes and night sweatsⓘ, joint pain, and sexual concerns appears comparable to high-income countries — but data on severity and burden are scarce, and most studies used methods that make direct comparison difficult (69).

The Workplace Gap

In a survey of 1,642 US employees, 83% had current or prior experience with menopause. The symptoms with the most workplace impact were sleep changes (63%), memory changes (49%), hot flashes (39%), and anxiety (39%). Nearly half (47%) reported difficulty concentrating, and 41% reported increased stress. Only 9% received any workplace support. The estimated annual cost in lost US workdays is $1.8 billion (71).

If Your Situation Is Different

Premature ovarian insufficiency (before age 40) and early menopause (ages 40-45) are clinically distinct situations where hormone therapy serves a different purpose — it functions as primary prevention for cardiovascular disease, type 2 diabetes, and osteoporosis, not merely symptom relief. Dosing, monitoring, and management logic all differ from standard menopause care. See the Special Populations section for full guidance.

Questions to Bring to Your Doctor

• "Could what I'm experiencing — the fatigue, the brain fog, the mood changes — be perimenopause?"
• "I've been told menopause symptoms last 2-5 years, but mine have lasted longer. Is that within the range of what's expected for someone like me?"
• "I'm still having periods — do I still need contraception? For how long after my periods stop?"
• "My symptoms started before age 45. Does that change how we should approach this?"

Menopause care can feel confusing — some advice conflicts, some research is incomplete, and some patients do not feel heard. But the picture is more complicated than it may seem. There is genuine scientific consensus on many of the questions that matter most to you. There are also real disagreements, and real gaps where the evidence simply does not exist yet.

This section maps what experts agree on, where they diverge, and where the evidence is thin — so you know where to trust the research and where to ask for a clear explanation of what is known, what is uncertain, and how that uncertainty affects your options.

There Is a Real Consensus Process

What Experts Agree On

Hormone therapy is the most effective treatment for hot flashes and night sweatsⓘ in eligible women. This is consensus across IMS, FIGO, NAMS, and ICSM. Route and formulation matter — an estrogen patchⓘ generally carries lower thrombotic risk than estrogen pillsⓘ in guideline framing, though that picture has important regimen-specific nuances covered in the Long-Term Health section.

Estrogen should not be prescribed solely to prevent cardiovascular disease. Despite favorable effects on some risk factors, guidelines are clear: CVD prevention is not an indication for starting hormone therapy.

Testosterone patch/gelⓘ is indicated only for low sexual desire disorderⓘ in postmenopausal women — not for cognition, general well-being, depression, or musculoskeletal health. IMS 2024 is explicit on this boundary.

Genitourinary syndrome of menopause (GSM) is chronic and progressive. It does not resolve on its own. Vaginal estrogenⓘ has the strongest evidence base, anchored to an AHRQ systematic review of 68 publications plus a 66-publication evidence map (61). Vaginal DHEAⓘ and ospemifeneⓘ are first-line pharmacological alternatives (86). Vaginal laser therapy has not shown benefit over sham in controlled trials and is not recommended for routine use.

Premature ovarian insufficiency (POI) requires hormone therapy as primary prevention — for cardiovascular disease, type 2 diabetes, and osteoporosis — not merely symptom relief. Doses are higher than standard menopause treatment. Complementary therapies do not substitute. The Special Populations section covers this in detail.

CBT-Iⓘ is specifically effective for insomnia during the menopausal transition (120). SSRIs and SNRIs are core treatments for major depressive disorder when it co-occurs. Newer non-hormonal VMS medications (neurokinin receptor antagonists) are emerging, with trial data covered in the Treatment Options section.

Where Guidelines Diverge

First-line treatment for perimenopausal mood symptoms is genuinely contested. FIGO 2026 allows hormone therapy as first-line when mood symptoms accompany vasomotor symptoms and sleep disruption. EMAS positions antidepressants as first-line even for mild depression. CANMAT places estrogen patchesⓘ as second-line for perimenopausal depression. The field has not resolved whether hormonally driven mood symptoms and clinical depression are distinct enough to warrant different first-line approaches — or whether that distinction is reliably made in clinical practice.

Breast cancer history changes the decision framework entirely. A 25-member multidisciplinary panel reached 100% agreement that MHT decisions after breast cancer should be individualized — weighing symptom severity, individual relapse risk, and patient preferences — rather than categorically ruled out (88). They also reached 100% agreement that combining systemic estrogen with an aromatase inhibitor is counterproductive. This is why the Breast Cancer & HRT section separates survivor contexts rather than relying on a single blanket statement.

The thrombotic risk picture is more regimen-specific than "transdermal is safer." Transdermal unopposed estrogen shows a favorable signal. But transdermal combined therapy carried a VTE signal in a large Swedish emulated target trial — a finding the broad shorthand does not cover. The Long-Term Health section breaks this down by regimen and endpoint.

Where the Evidence Is Thin

Not all gaps are equal. Some are areas where research is simply early; others are areas where uncertainty can leave patients without clear options.

Bone-health prevention in asymptomatic women. The 2023 IMS/AMS/BMS Practitioner's Toolkit found no clear guidance on when hormone therapy might be indicated to prevent bone loss in women without symptoms — and expanded shared decision-making for this situation (27).

Mental health screening and LMIC populations. No standardized mental health guidelines for menopausal women exist. Most validated screening scales were developed in English-speaking populations. Women in low- and middle-income countries face inconsistent evidence bases and limited tool availability (120, 107).

GSM diagnosis. There is no consensus on the number or type of symptoms needed to diagnose GSM. Urinary symptoms overlap with overactive bladder and other urologic conditions, and sexual pain can stem from pelvic floor dysfunction, lichen sclerosus, or vestibulodynia rather than GSM alone (61, 86).

POI formulation evidence. No randomized controlled trials compare hormone therapy formulations specifically in women with POI. Asian POI data are limited. Optimal dosing across the reproductive age range is unknown (60).

Complementary therapies. A systematic review of 158 studies (114 RCTs) found moderate-certainty evidence only for black cohoshⓘ, certain Chinese herbal medicines, and vitamin D for fracture risk. Most other therapies had low or very low certainty. 54% of included RCTs had high risk of bias, and 72% of the reviews scored critically low on the AMSTAR2 quality tool (109).

Sexual function during perimenopause specifically. A Cochrane review of 36 RCTs (23,299 women) found that only 1 trial evaluated perimenopausal women. None enrolled only women with sexual dysfunction. Only 7 studied sexual function as their primary outcome. 20 of 36 had high risk of bias (22).

Sarcopenia. IMS 2025 flags muscle health during menopause as requiring "urgent attention" — but a systematic review of 43 studies found no consistent evidence that hormone therapy prevents or treats sarcopenia. None of the included studies used modern consensus sarcopenia definitions (68).

Breast cancer risk quantification after hormone therapy. Robust randomized trial evidence to precisely quantify risk and benefit magnitude for women with breast cancer history does not yet exist. The cited expert panel recommends the MENO-ABC trial for patients considering this decision (88).

The Shared Decision-Making Principle

Across all of these areas — consensus, disagreement, and gap — one principle recurs: shared decision-making between you and your doctor, based on your specific situation, is how the field handles the places where evidence is strong but individual risk varies, or where evidence is thin. This is not a hedge. It is the method the guidelines themselves recommend when one-size-fits-all answers do not exist.

Questions to Bring to Your Doctor

• "Which guideline framework do you use when making menopause treatment decisions — IMS, NAMS, or something else?"
• "For my specific symptoms, is the evidence strong enough for a clear recommendation — or is this an area where we're making a judgment call together?"
• "Are there areas where the evidence has changed recently that might affect my treatment plan?"
• "I've heard conflicting things about [specific topic]. Can you walk me through what the current research actually says?"

The treatment landscape for perimenopause is broader than most women realize — and the evidence behind each option varies dramatically. This section maps what is available, what the research supports, and where the evidence is thin or absent. It is organized by type of option, not by a suggested order.

Your decisions about treatment belong with you and your doctor, based on your specific symptoms, medical history, and preferences. Several of these options are explored in more detail in later sections: mood and sleep in the Mood, Sleep & Cognition section; hot flashes in the Vasomotor Symptoms section; genitourinary symptoms in the Genitourinary Health section; long-term cardiovascular, metabolic, and bone considerations in the Long-Term Health section; breast cancer context in the Breast Cancer & HRT section; and specific situations including premature ovarian insufficiency in the Special Populations section.

Behavioral and Self-Management Options

Symptom Self-Monitoring

Cognitive Behavioral Therapy for Insomnia (CBT-I)

Mind-Body Therapies

A systematic review and meta-analysis of 18 randomized controlled trials (1,572 women) found that mind-body therapies produced a large effect on sleep quality (SMD -0.86) — larger than their effect on depression (SMD -0.79) (102). Yoga and Qigong showed the most stable benefits for sleep; mindfulness and music therapy were more effective for emotional regulation.

Yoga specifically has been studied across 14 RCTs (1,057 women) and appears beneficial for overall menopausal symptoms compared to no treatment, with possible improvements in anxiety, depression, sleep, BMI, and blood pressure — though the evidence is low certainty with high heterogeneity (109).

Exercise

One important finding: in a Dutch cohort study of 9,942 women, menopausal symptom burden was strongly associated with high need for recovery after work (OR 4.51 per 10-point symptom increase), and lifestyle behaviors — including physical activity — did not moderate that association (94). Exercise independently benefits mood and recovery, but it does not buffer the workplace impact of menopausal symptoms. Workplace support should not depend on whether a woman exercises.

Supplements and Complementary Therapies

The evidence quality across complementary therapies is generally low. A systematic review of 158 studies (114 RCTs) found that 54% of included RCTs had high risk of bias, and 72% of the systematic reviews scored critically low on the AMSTAR2 quality tool. Only 6 of 114 RCTs were assessed as low risk of bias (109). That does not mean nothing works — but it means the strongest claims often rest on the weakest evidence.

Black cohosh (isopropanolic extract) has the strongest complementary therapy signal — moderate-certainty evidence from 22 RCTs (2,310 women) showing benefit for vasomotor symptoms and overall menopausal symptoms. It is generally safe (109).

Soy isoflavones show a small but statistically significant effect on overall menopausal symptoms (Hedges' g = -0.25, I²=0% — consistent across studies). Soy-derived isoflavones, not red clover-derived, showed benefit for hot flash frequency. The Genitourinary Health section covers a separate vaginal-dryness signal with high heterogeneity. Effects on breast tissue depend on endogenous estrogen concentrations, and women with estrogen-sensitive cancers or on anti-estrogen medication should discuss soy supplementation with their clinician (77).

Ashwagandha root extract showed a large effect on menopausal symptoms in one small trial (n=60, 56 days) using a specific branded product (KSM-66, supplied by Ixoreal Biomed Inc). The authors explicitly state that results may not be extrapolated to other ashwagandha preparations. The unusually large effect size and minimal placebo response warrant caution — this is a single-center, single-product, 8-week signal, not established evidence for ashwagandha as a category (111).

Evening primrose oil does not have sufficient evidence to support its use for hot flashes. A systematic review found no significant effect on hot flash frequency or duration. A short-term severity signal (<6 months) did not persist, and at 8 weeks EPO performed worse than black cohosh for severity (p=0.001). The authors concluded: "currently insufficient evidence to conclude that EPO is beneficial to alleviate hot flashes" (51).

Vitamin D and calcium have moderate-certainty evidence for reducing hip fractures in postmenopausal women over 65 with osteoporosis. In the general population, the WHI 13-year follow-up found no fracture difference. High-dose calcium (>1,000 mg/day) may raise blood pressure, and long-term calcium plus vitamin D supplementation may increase cardiovascular mortality after 7 years. Vitamin D itself has high-certainty safety evidence (109).

Manual acupuncture was not superior to sham for hot flash severity or frequency. Omega-3 showed no effect on hot flashes or sleep. High-dose vitamin E (≥400 IU/day) is associated with increased all-cause mortality (109).

Hormone Therapy

Hormone therapy remains the most effective treatment for hot flashes and night sweatsⓘ in eligible women — this is consensus across IMS, FIGO, NAMS, and ICSM. But "hormone therapy" is not one thing. Formulation, route, dose, and the specific progestogen all affect both efficacy and risk.

Route and Formulation

However, the "transdermal is safer" shorthand needs qualification. A large Swedish study (919,614 women) found that transdermal estrogen used as part of combined estrogen-progestogen therapy still carried a VTE signal (HR 1.46-1.67), while transdermal unopposed estrogen did not. The Long-Term Health section breaks this down by specific regimen and endpoint.

In women with type 2 diabetes at low cardiovascular risk, estrogen pill (estradiol)ⓘ showed advantages for glucose metabolism (33) — the opposite of the general route preference for cardiovascular safety. This is one of several areas where route selection depends on which comorbidity dominates a woman's individual risk profile.

Oral Micronized Progesterone — Why Bedtime Dosing Matters

When taken orally, less than 20% of natural progesteroneⓘ circulates as progesterone itself. About 80% is converted into neurosteroid metabolites — allopregnanolone and pregnanolone — that act on GABA receptors in the brain (39). These metabolites are thought to explain why oral micronized progesterone can be sedating and may support sleep — effects that synthetic progestinsⓘ do not share, because they do not convert to these neurosteroids. Bedtime dosing is commonly used because drowsiness and dizziness can occur. Vaginal progesterone does not produce these neurosteroid effects at clinically significant levels. Note: the clinical sleep trial below tested oral micronized progesterone combined with transdermal estradiol — not oral MP alone.

[EVIDENCE] In the PERT trial (n=172, 12 months), transdermal estradiol 0.1 mg/day plus intermittent oral micronized progesterone improved sleep independently of its effects on hot flashes and depression (p=0.02 after controlling for both). This suggests a direct hormone-on-sleep pathway. (PMID 31688579, ref 6, PMID 31838497, ref 7)

For Mood Symptoms Specifically

Guideline discussions often favor an estrogen patch or gelⓘ when mood symptoms are being treated hormonally and metabolic or thrombotic risk is relevant. CANMAT positions transdermal estrogens as second-line for perimenopausal depression (120). In a three-arm RCT (n=195, 12 weeks), the combination of an estrogen-progesterone combination pillⓘ plus escitalopramⓘ significantly outperformed either treatment alone for both depression and anxiety scores (124). A parallel trial (n=166) showed the same combination pattern for insomnia (65).

For Genitourinary Symptoms

Vaginal estrogenⓘ has the strongest evidence base for genitourinary syndrome of menopause, anchored to an AHRQ systematic review of 68 publications. Multiple formulations exist (estradiol tablets, softgel inserts, rings, creams; estriol gels and inserts; promestriene) — all show class-effect efficacy, and the choice is based on patient preference to support adherence. At recommended doses, local vaginal estrogen does not raise circulating estradiol above normal postmenopausal levels (86, 61).

Vaginal DHEAⓘ reduces dyspareunia and vaginal dryness with minimal systemic sex-steroid increase. Ospemifeneⓘ is now considered a first-line pharmacological alternative alongside local estrogen after 5-year VTE safety data (86). Vaginal laser therapyⓘ has not shown benefit over sham in controlled trials and is not recommended for routine clinical use.

The Genitourinary Health section covers these options in full detail.

For Premature Ovarian Insufficiency

In women with POI (ovarian activity lost before age 40) or early menopause (ages 40-45), hormone therapy functions as primary prevention for cardiovascular disease, type 2 diabetes, and osteoporosis — not merely symptom relief. Doses are higher than standard menopause treatment, and therapy continues until the usual age of natural menopause (~50). The Special Populations section covers POI-specific dosing, monitoring, and management.

Non-Hormonal Prescription Options

SSRIs and SNRIs

SSRIs and SNRIs are core treatments for major depressive disorder during menopause (FIGO consensus). Specific evidence-based options include escitalopramⓘ, venlafaxineⓘ, and paroxetine (for depression)ⓘ. Paroxetine (low-dose for hot flashes)ⓘ is available separately from the depression dose. Venlafaxine also reduces hot flashes (120).

These medications carry their own tradeoffs: sexual dysfunction is common with SSRIs, SSRIs are associated with increased fracture risk, and SSRIs, pregabalin, and gabapentin all carry withdrawal and dependency concerns. Anticholinergic medications carry cognitive-decline risk. These side effects should be weighed honestly against the side effects of the symptoms themselves — and against the side effects of leaving symptoms untreated (88).

Neurokinin Receptor Antagonists

This is a new class of non-hormonal prescription medications that target the thermoregulatory pathways involved in hot flashes. Fezolinetantⓘ was not significantly different from hormone therapy for VMS frequency reduction in an indirect network comparison (29). It carries an FDA black box warning for hepatotoxicity, requiring liver function testing before treatment and frequently during the first 9 months (64). Elinzanetantⓘ showed no hepatotoxic signal but had higher rates of treatment-emergent adverse events and discontinuations. The Vasomotor Symptoms section covers the trial evidence for both in detail.

Testosterone

Testosterone is indicated for hypoactive sexual desire disorder (HSDD) in postmenopausal women — not for general well-being, cognition, depression, or musculoskeletal health. Testosterone patch/gelⓘ consistently improves sexual desire, arousal, orgasm frequency, and reduces sexual distress in women with HSDD (53). In the available trial and review data, common androgenic side effects such as localized hair growth and acne were generally mild and reversible.

Pilot data suggesting mood benefit (47% improvement, n=510) is hypothesis-generating only — a larger UK clinic dataset (n=920) found that adding testosterone to estradiol did not significantly improve mood beyond estradiol alone (p=0.47) (43, 66).

Contraception During Perimenopause

Perimenopause requires ongoing contraception — pregnancy remains possible during the transition. Women over 50 need contraception for 1 year after their final menstrual period; women under 50 need it for 2 years. No contraceptive method is contraindicated solely by age, and natural estrogen-containing formulations are preferred after 40 (84). The Making Your Decision section discusses how contraception fits into the broader treatment-planning conversation.

For Women Who Cannot Use Hormone Therapy

Questions to Bring to Your Doctor

• "Given my specific symptoms and medical history, which treatment category makes the most sense to start with — and why?"
• "If we're considering hormone therapy, what specific formulation, route, and dose are you recommending — and what is the evidence behind that choice?"
• "What are the realistic side effects of this treatment, and how do they compare to the side effects of leaving my symptoms untreated?"
• "Are there options I can try alongside or before prescription treatment — like CBT-I for sleep or structured exercise for mood?"
• "I have [specific condition]. Does that change which options are available to me?"

The right question is not "should I take hormone therapy?" It is: which specific treatment, delivered how, at what dose, at what point in your transition, makes sense for your situation? The answer depends on individual factors — your symptoms, your medical history, your risk profile, and your preferences — and those factors can change the treatment calculus in opposite directions.

This section maps the decision factors that matter most. For the treatment options themselves, see the Treatment Options section. For specific symptom domains, see the relevant later sections.

Route and Formulation Affect Safety

One important qualification: a large Swedish study (919,614 women) found that estrogen patch used as part of a combined hormone regimenⓘ still carried a VTE signal (HR 1.46-1.67), while estrogen patch alone (without a progestogen)ⓘ did not. "Transdermal is safer" is not a complete statement — route, the specific progestogen, and the specific outcome (clotting vs stroke vs arterial disease) all need to be separated. The Long-Term Health section breaks this down in detail.

In women with type 2 diabetes at low cardiovascular risk, estrogen pill (estradiol)ⓘ showed advantages for glucose metabolism (33) — the opposite direction from the cardiovascular route preference. Which route is best depends on which risk dominates your individual profile.

If You Have a Breast Cancer History

Breast cancer history changes the decision framework entirely — and the specifics depend on what kind of breast cancer.

ER-positive breast cancer: In the cited expert-panel framework (25-member modified Delphi, 88), systemic MHT after ER-positive breast cancer is treated as higher-risk, especially within 5-10 years of diagnosis, with magnitude proportional to background risk. The panel reached 100% agreement that combining systemic estrogen with an aromatase inhibitor is counterproductive. The panel discusses rare off-label consideration only through careful shared decision-making — if systemic MHT is chosen, a low-dose estrogen patch with natural progesteroneⓘ is the formulation discussed.

ER-negative breast cancer: The expert-panel framework treats relapse risk differently after ER-negative disease because residual cells lack estrogen receptors. However, there is approximately a 1% per year risk of a second breast cancer, roughly half of which are ER-positive. Estrogen-only therapy may decrease second-cancer risk in limited data.

DCIS (ductal carcinoma in situ): The expert-panel framework considers DCIS differently from invasive breast cancer — DCIS is usually curable, and the risk-benefit balance may differ. However, direct MHT safety data after DCIS are absent — no studies have evaluated this specifically. One additional consideration: hormone therapy can increase mammographic density, which decreases screening sensitivity — a concern separate from the direct recurrence question.

For all three subgroups, the decision framework is the same: weigh symptom severity and quality-of-life impact against individual relapse risk, with patient preferences central to the conversation. The Breast Cancer & HRT section covers the evidence in full.

Treating menopausal symptoms may also protect cancer treatment adherence. The same expert panel reached 100% agreement that patients are more likely to continue their adjuvant endocrine therapy (tamoxifen, aromatase inhibitors) when menopausal side effects are managed. Non-adherence to these cancer treatments worsens breast cancer outcomes — so treating menopausal symptoms is not separate from cancer care; it supports it (88).

If You Have Premature Ovarian Insufficiency or Early Menopause

In women with POI (before age 40) or early menopause (ages 40-45), the decision logic is fundamentally different. Guidelines generally frame hormone therapy as primary prevention — for cardiovascular disease, type 2 diabetes, and osteoporosis — rather than symptom-only treatment, even when symptoms are mild or absent. Doses are higher than standard menopause treatment, and therapy continues until the usual age of natural menopause (~50). Contraindications are narrower than in standard menopause care, with estrogen-sensitive cancer a key exception. See the Special Populations section for full dosing and monitoring guidance (60).

Timing and Duration

When hormone therapy is started matters. Early initiation — within 10 years of menopause or before age 60 — is associated with a more favorable cardiovascular benefit-risk profile (4). Guideline discussions commonly emphasize lower effective dosing, shorter duration, and transdermal route when initiation is later.

Contraception During the Transition

If you are still having periods or are within 1-2 years of your last period, contraception remains necessary. Options include the hormonal IUDⓘ (which also provides endometrial protection if you are using estrogen), progestogen-only implants, and combined pills with body-identical estrogen — which can provide symptom relief and contraception together. Injectable contraceptives are generally used only until about age 50 due to bone density concerns (53).

Bone Health Without Symptoms

If you have no menopausal symptoms but are concerned about bone loss, the decision is less clear-cut. Guidelines lack consensus on when hormone therapy might be indicated purely for bone-loss prevention in asymptomatic women — this is a gap area where shared decision-making applies (27). What the evidence does show: hormone therapy reduces fracture risk regardless of fall risk or baseline FRAX score, and non-hormonal vasomotor symptom treatments do not provide bone protection (53). If bone health is your primary concern and you have no symptoms driving a treatment decision, this is a conversation about prevention strategy, not symptom management.

Inherited VTE Susceptibility

The Progestogen Matters Too

Most discussion of hormone therapy focuses on estrogen. But if you have a uterus and take estrogen, you also need a progestogen for endometrial protection — and the type of progestogen affects mood, sleep, breast cancer risk, and cardiovascular/metabolic outcomes independently. Micronized progesterone and dydrogesterone often show more favorable profiles than several synthetic progestins across these domains, but the best choice depends on the specific comparator, route, population, and outcome being considered. The formulation-dependence framework applies to both the estrogen and the progestogen component of any hormone therapy regimen.

Questions to Bring to Your Doctor

• "Given my medical history, which specific formulation, route, and dose are you recommending — and what evidence supports that choice for someone in my situation?"
• "I had [ER+/ER-/DCIS] breast cancer. What does the current evidence say about hormone therapy for my specific subtype?"
• "I'm considering starting hormone therapy [early in my transition / later]. How does timing affect the risk-benefit balance for me?"
• "Do I still need contraception? If so, is there an option that also helps with my menopausal symptoms?"
• "I don't have symptoms but I'm concerned about bone health. Is there evidence for starting treatment purely for prevention?"
• "Do I have any risk factors — family history of clots, metabolic conditions, specific cancer history — that should change which route or formulation we choose?"

Perimenopause produces a wide range of symptoms, and many common symptoms are uncomfortable, disruptive, and often unrecognized without being, by themselves, evidence of serious disease. This section separates the patterns where the evidence calls for clinical attention from those that are broadly reassuring at the population level.

Patterns Where the Evidence Calls for Prompt Clinical Attention

Suicidal Thoughts During Perimenopause

Persistent Insomnia as a Cardiovascular Signal

Depression Risk Is Not Universal — but Specific Groups Are Vulnerable

Women with a prior history of major depressive disorder had a 59% recurrence rate during midlife, compared to 28% without prior history — and 13 times more depressive symptoms during perimenopause (120). In a 19-year SWAN longitudinal study, women with consistently high depressive symptoms before their final menstrual period were the highest-risk group for postmenopausal depression (OR 6.88); the moderate-symptom group also had elevated risk (OR 2.62). The pre-FMP trajectory was a stronger predictor than concurrent factors (12).

If you have a history of depression, this is worth discussing with your doctor as you enter the perimenopausal transition — the evidence supports proactive monitoring rather than waiting for symptoms to worsen.

Patterns to Raise With Your Doctor

Mood and Cognitive Symptoms That Don't Add Up

Mood and cognitive symptoms during perimenopause can be mistaken for other medical or mental health conditions, delaying appropriate care. Differentiating menopause-linked symptoms from pathological depression involves evaluating timing relative to the menstrual cycle and transition stage, symptom severity, personal history, and risk factors. Screening tools such as the PHQ-9, GAD-7, and menopause-specific scales can help orient the conversation, but clinical evaluation — not scales alone — makes the distinction (120, 107). See the Mood, Sleep & Cognition section for the full evidence on cognitive and mood symptoms.

Abnormal Uterine Bleeding — Often Normal, Sometimes Not

Irregular bleeding during perimenopause is often physiologic — anovulation leads to insufficient progesterone and irregular shedding. But the source literature explicitly states this should not be assumed without ruling out concerning causes.

Patterns the source literature highlights for evaluation: intermenstrual or postcoital bleeding. In cited questionnaire studies, self-reported heavy menstrual bleeding was much less likely to resolve without recurrence over 24 months (9.8%, 95% CI 7.7-12.4%) compared to intermenstrual or postcoital bleeding (57%, 95% CI 52-63%). Endometrial-cancer risk factors that lower the threshold for workup include family history, HNPCC/Lynch syndrome, PCOS, tamoxifen use, and elevated waist-to-hip ratio. Anemia from heavy bleeding is a separate concern that warrants treatment on its own merits (34).

AUB visits may be an opportunity for mental health screening. In a Chinese retrospective cohort of 1,234 perimenopausal women with AUB, 33.9% had comorbid anxiety and depression — the largest of four subgroups. This is association data, not causal evidence — AUB does not cause depression. But the co-occurrence rate suggests that women presenting with heavy or irregular bleeding may benefit from depression, anxiety, and sleep screening alongside gynecological assessment (63).

A structural care gap exists in AUB evaluation. In a US national dataset of 7.9 million ED visits for non-pregnancy AUB (2014-2021), Black patients had less than half the odds of receiving ultrasound or referral compared to White patients (composite aOR 0.46). Perimenopausal-age women (46-55) had significantly lower odds of ultrasound (aOR 0.47) and referral (aOR 0.31) compared to younger women — the study authors note that providers may normalize bleeding at this age. Rural patients faced the steepest disparity (composite aOR 0.13). This is a structural process-of-care finding, not a patient-behavior gap (80).

Genitourinary Symptoms That Persist or Worsen

GSM is chronic and progressive — genitourinary symptoms do not resolve without treatment. Symptoms and signs return approximately 1 month and 3 months respectively after discontinuing effective treatment (86). If you are experiencing vaginal dryness, urinary symptoms, or sexual pain that has persisted or worsened, this is worth discussing with your doctor rather than waiting — see the Genitourinary Health section.

Sexual pain is not always GSM. Dyspareunia in postmenopausal women may reflect pelvic floor hypertonus, surgical sequelae, lichen sclerosus, vestibulodynia, or pelvic organ prolapse — not only vaginal atrophy. Trauma history also affects presentation: in the cited ICSM evidence, sexual assault history was associated with 2.5 times the odds of vaginal symptoms, and emotional abuse with approximately twice the odds of urinary incontinence. A differential assessment is appropriate before attributing sexual pain to GSM alone (86).

Provider-Initiated Conversations Are Largely Absent

Across multiple studied populations — African American women in the US (0% provider-initiated, 110), immigrant Muslim women in the UK (55), women in Nigeria (114), and women in Oman (118) — provider-initiated menopause conversations are essentially absent. This is a gap in how care is delivered, not something patients have missed. If your visits haven't covered menopause and you'd like them to, this is worth raising at your next appointment.

New Sleep Disruption as an Early Signal

In a longitudinal study tracking symptoms every 2-6 months, "trouble sleeping because of feeling too hot" preceded conscious awareness of hot flashes by approximately 6 months (18). Unexplained new sleep disruption in midlife — especially accompanied by feeling hot — may signal the beginning of the menopausal transition before other symptoms become apparent.

Skin, Hair, and Oral Symptoms Often Go Unconnected

In a small specialist menopause-clinic survey (n=50, 58), 48% of women had self-managed skin symptoms without consulting a doctor, often for months before connecting them to perimenopause. These symptoms are common but frequently unrecognized as menopause-related — see the Body Changes section. Dry-eye symptoms are also prevalent in midlife women (64.9% in a Thai clinic study, 82) but hormone therapy's effect on dry eye is inconsistent in the broader literature.

Patterns the Evidence Finds Broadly Reassuring

Palpitations

About half of women experience moderate-to-high palpitations during perimenopause and early postmenopause, diminishing in late postmenopause. In SWAN (n=3,276), fully adjusted models found that palpitation trajectories were not independently associated with subclinical cardiovascular disease markers (carotid intima-media thickness, pulse wave velocity) after accounting for BMI, blood pressure, glucose, and sleep (13). At the population level, this is reassuring. Chest pain, syncope, or persistent new arrhythmia fall outside the reassuring pattern described in this study and are appropriately evaluated in a clinical setting.

Brain Fog

Cognitive changes during perimenopause — difficulty concentrating, word-finding problems, feeling mentally slower — are real and documented. For most women, these changes reflect shifts in attention rather than memory decline, and they tend to improve during postmenopause. For most women, this pattern does not by itself point to dementia. If your cognitive symptoms are severe, started suddenly, or are progressively worsening rather than fluctuating, that is a different pattern worth discussing with your doctor (53). See the Mood, Sleep & Cognition section for the full cognitive evidence.

Questions to Bring to Your Doctor

• "I've been having [specific symptom]. Could this be related to perimenopause, or should we investigate other causes?"
• "I have a history of depression. Given the evidence about recurrence risk during perimenopause, should we set up proactive monitoring?"
• "My sleep has changed significantly. Is this the kind of persistent pattern that the cardiovascular evidence is about, or is it likely to resolve?"
• "I've had irregular bleeding for [duration]. Given my age and risk factors, does this need workup or is it likely physiologic?"
• "I've been managing [skin/hair/urinary/sexual] symptoms on my own for a while. Could these be menopause-related?"

"Am I going crazy?" "Why can't I sleep?" "Is this brain fog?" These are the questions women bring to this section. The evidence addresses all three — and the most important thing the research shows is that these are connected but distinct, each with its own evidence base and its own trajectory.

Mood

What the Evidence Shows About Depression During Perimenopause

Between 45% and 68% of women experience heightened depressive symptoms during perimenopause — about 1.4 times more likely than during the premenopausal years. But most women remain stable. Australian longitudinal data found that only about 9% had increasing depressive symptoms linked specifically to the transition, oophorectomy, or hormone therapy changes (120).

The evidence is clear: the menopausal transition alone does not universally increase risk for depression. Specific subgroups carry the elevated risk — women with severe vasomotor symptoms, sleep disturbances, sensitivity to estrogen changes, early or surgical menopause, prior history of mental health disorders, or significant psychosocial stressors (120).

If you have a history of major depressive disorder, the numbers are different. Women with prior MDD had a 59% recurrence rate during midlife, compared to 28% in women without prior history — and 13 times more depressive symptoms during perimenopause (120). In a 19-year SWAN longitudinal study, women with consistently high depressive symptoms before their final menstrual period had an odds ratio of 6.88 for postmenopausal depression. Childhood trauma and maltreatment were enduring risk factors independent of everything else. Social support was protective (12).

Symptom prevalence varies globally and across populations. A meta-analysis of 265 studies (349,608 women) found a global depressive symptom prevalence of 43%, ranging from 22% in White women to 27% in Black women in the SWAN cohort, and reaching 82% in a Cambodian sample. Among 334 African American women, 83% reported anhedonia, 80% fatigue, 74% anxiety, and 73% feeling down or hopeless — alongside a 69% comorbidity rate for hypertension, diabetes, or heart disease (120, 110).

"Not Feeling Like Myself"

The symptoms that drive the experience of perimenopause are not the ones most commonly associated with it. In a study of 1,263 women (38), five symptom groups predicted the feeling of "not feeling like myself": anxiety and vigilance (β=0.220), fatigue and pain (β=0.192), brain fog (β=0.123), sexual symptoms (β=0.121), and volatile mood (β=0.083). Together they explained 41.8% of the variance in identity disruption. Hot flashes and vaginal dryness were weaker predictors. If you feel like you are losing yourself, that experience has a measurable pattern in the research.

Perimenopause Anxiety Is Not Always Generalized Anxiety Disorder

Women describe perimenopause-related anxiety differently from clinical GAD. Rather than excessive worry occurring most days for six months or more, they describe "decreased tolerance for stress" and "insignificant things becoming major stressors." This is linked to fluctuating estrogenⓘ affecting cortisol and catecholamine pathways — a different mechanism from trait anxiety (38).

Volatile mood — irritability, sudden mood changes, sudden anger or rage — may be a standalone perimenopause symptom rather than a component of depression. The evidence suggests it is linked to different estrogen-change patterns than depressive symptoms (38).

The Depression Contradiction — Does Hormone Therapy Help or Hurt?

You may encounter conflicting information about whether hormone therapy helps depression during perimenopause. Both claims have real studies behind them.

Under controlled conditions with specific formulations, hormonal therapy helped. A three-arm randomized controlled trial (n=195, 12 weeks) found that an estrogen-progesterone combination pillⓘ combined with escitalopramⓘ significantly outperformed either treatment alone for depression and anxiety scores (124). The largest UK specialist menopause clinic (n=920) reported a 44.59% reduction in depression scores after MHT initiation or optimization, with all regimens effective — natural progesteroneⓘ and hormonal IUDⓘ alike (66).

In real-world prescribing data, systemic hormone therapy was associated with increased depression risk. A Danish register study following 825,238 women found systemic HT associated with about 70% higher risk of depression in the first year (HR 1.72), with risk highest in younger women aged 48-50 (14). A Korean multi-database study of 17,098 women found similar results — HRT during the symptomatic menopausal transition was associated with more than double the depression risk (HR 2.21) (24).

Why the disagreement? The positive evidence came from defined clinical contexts — oral estradiol/dydrogesterone plus escitalopram in one RCT, and MHT initiation/optimization in one specialist-clinic dataset — under controlled or specialist conditions. The register studies captured all real-world prescribing with mixed and unspecified formulations. Confounding by indication is likely: women prescribed HRT are also more likely to be experiencing symptoms that lead to a depression diagnosis. However, the Danish data showed that HT users were actually healthier at baseline, which complicates a simple confounding explanation. The answer to "does hormone therapy help depression?" depends on which hormone therapy, for whom, at what timing, and with what progestogen.

One route-dependent finding adds perspective: in the same Danish data, vaginal estrogenⓘ was associated with lower depression risk in women over 54 (HR 0.80) — the opposite direction from systemic HT. One plausible explanation is that treating genitourinary symptoms may improve quality of life, which could affect mood (14).

ADHD and Perimenopause Overlap

ADHD and perimenopause share substantial symptom overlap — brain fog, difficulty concentrating, mood swings, emotional dysregulation. The key distinction is timing: ADHD symptoms are typically present from childhood, while perimenopause-linked cognitive and mood symptoms emerge in midlife (125). See the Special Populations section for the full ADHD evidence, including medication and hormone therapy considerations.

Non-Pharmacological Options for Mood

CBT is specifically recommended by NICE guidelines for depressed mood during menopause. Mindfulness-based therapy has shown improvements in menopause-specific quality of life and reductions in anxiety, depression, and stress, though some of these effects need further validation. Vitamin D supplementation may improve anxiety more than depression in the available evidence, though certainty is limited (120). See the Treatment Options section for exercise dosing and the full non-pharmacological evidence.

Sleep

Sleep disruption during the menopausal transition is not a secondary symptom of hot flashes — the evidence establishes it as an independent health concern with its own trajectory, its own cardiovascular consequences, and its own treatment evidence.

Sleep Is Often the First Change

How Common Is It?

Insomnia prevalence was 31-42% at any given SWAN assessment visit, with late perimenopause carrying about 30% higher odds than early perimenopause (1). In a German survey of 26,338 peri- and postmenopausal women, 90.3% had at least some sleep disturbance and 48% met criteria for clinical insomnia (93).

Among postmenopausal women, those with sleep disturbances alone had worse quality-of-life outcomes than those with vasomotor symptoms alone (p<0.001) — in a study of 47,841 women across the US and Europe (95). Sleep is not just a side effect of hot flashes. It has its own impact.

Treatment Evidence for Sleep

CBT-I is the behavioral treatment with the strongest evidence — see the Treatment Options section for remission rates and delivery format.

Combination estrogen-progesterone pillⓘ plus escitalopramⓘ outperformed either alone for insomnia in a parallel 3-arm trial (n=166, 12 weeks) — the same dual-pathway pattern seen in the depression trial (65).

Mind-body therapies produced a large pooled effect on sleep (SMD -0.86, 18 RCTs, 1,572 women), with yoga and Qigong showing the most stable signals for sleep specifically and mindfulness and music therapy better for emotional regulation (102). These effect sizes are promising but come with high heterogeneity (I²=88%) and most modality comparisons rest on 1-2 studies — symptom-driven and feasibility-driven choices are more appropriate than a strict hierarchy.

Dual orexin receptor antagonists (suvorexant, daridorexant, lemborexant) are emerging as pharmacological options that target the orexin system directly (129).

Cognition

Layer 1 — What Brain Fog Actually Is

Cognitive changes during perimenopause — difficulty concentrating, word-finding problems, feeling mentally slower — are real, hormonally linked, and documented in objective testing. But for most women, they reflect relative decline from their own baseline, not absolute impairment.

In a study that tracked over 1,500 women in the US and Canada, forgetfulness was the single most bothersome symptom — rated higher than hot flashes, anxiety, or pain — for women in both late reproductive stage and menopausal transition (38).

Interestingly, several symptoms women associate with menopause — fatigue, headache, anxiety, brain fog — are common at similar rates across pre-, peri-, and postmenopausal women (50). This does not mean they are not real during perimenopause. It means the transition may amplify an experience that is not exclusive to it.

Layer 2 — Long-Term Dementia Risk Is a Separate Question

The relationship between hormone therapy and long-term dementia risk is genuinely uncertain. Three large datasets disagree, and the disagreement is informative.

[EVIDENCE] A WHO-commissioned systematic review and meta-analysis (10 studies, over 1 million women) found no overall significant association between hormone therapy and dementia or mild cognitive impairment. The only included randomized trial (WHIMS, women 65 and older at initiation) found combined therapy associated with higher probable dementia risk (HR 1.76), but this was a modest absolute excess of about 7 per 1,000 women. Several very-low-certainty subgroup signals pointed in different directions depending on formulation, duration, and timing. There was insufficient data to evaluate the effects of route, estrogen type, progestogen type, or dose. (PMID 41448220, ref 106)

A Danish nationwide study (5,589 dementia cases, 55,890 controls, 19-year follow-up) found that combined oral estrogen-plus-progestogen therapyⓘ — predominantly with synthetic progestins like norethisteroneⓘ (83.5%) — was associated with higher all-cause dementia risk that increased with duration. Progestin-only therapy and vaginal estrogen-only were not significantly associated. The study had no data on natural progesteroneⓘ (19).

A Korean register study (1,399,256 women) found formulation-stratified signals: tiboloneⓘ and oral estrogenⓘ were each associated with slightly elevated Alzheimer's risk; estrogen patchⓘ was not significantly associated, but the transdermal subgroup was small (n=2,081) with wide confidence intervals — making this weak negative evidence rather than positive evidence of safety (26).

What this means for you: The current evidence does not support using hormone therapy for the purpose of preventing dementia. The European Society of Human Reproduction and Embryology recommends HT for dementia prevention in premature ovarian insufficiency, but the WHO-commissioned review found no studies supporting that specific indication. The established evidence base for hormone therapy is stronger for other indications — vasomotor symptoms, genitourinary health, and bone protection — than for dementia prevention.

Questions to Bring to Your Doctor

• "My mood has changed significantly since perimenopause started. How do we figure out whether this is hormonally driven or something else?"
• "I have a history of depression. What does the evidence say about monitoring and treatment during the transition?"
• "My sleep problems seem independent of my hot flashes — they don't always coincide. Does that change the treatment approach?"
• "I'm having brain fog that's affecting my work. Is this the kind of cognitive change that tends to improve, or should we investigate further?"
• "I've read conflicting things about hormone therapy and depression. Can you explain what the current evidence shows for someone in my specific situation?"

Hot flashes and night sweats — vasomotor symptoms, or VMS — are the most recognized menopause symptoms. But recognized is not the same as most experienced or most impactful.

What VMS Are — and What They Are Not

Hot flashes cluster independently from mood, sleep, and cognitive symptoms in analyses of over 147,000 symptom logs from nearly 5,000 women (50). They are the stage-specific hallmark of perimenopause, but they are not the causal hub for the broader menopause experience.

In a US discrete choice experiment (467 women with peri- or postmenopausal VMS), sleep improvement was the most valued treatment attribute (preference weight 0.843), ranked above VMS frequency reduction (0.658) and VMS severity reduction (0.628). Breast cancer risk (0.401) and cardiovascular risk (0.150) had less influence on treatment choice (23). When considering treatment for VMS, the sleep impact deserves attention alongside frequency and severity.

VMS Experience and Care-Seeking Vary by Population

How women experience and manage VMS varies across populations. In Japan, severe VMS affected 6.4% of a 2,188-woman sample, and even among those with severe symptoms, only about 25% visited a medical facility. The primary reason for not seeking care was self-coping — 50.3% reported "I tolerate without visiting" and 28.4% "I deal with by myself." Among those who did seek care, traditional Chinese medicine (Kampo) was prescribed for 55.7% and hormone therapy for 33.2%. The estimated annual cost of VMS-related presenteeism in Japan was approximately 370 billion yen. Only about 40% of women with severe VMS received a Konenki disorder diagnosis (76).

Health Implications — What the Evidence Shows

VMS and Alzheimer's Biomarkers

Physical Activity and Vascular Significance

In a small study of 52 healthy, already-active perimenopausal women (mean physical activity 87 minutes per day — well above guidelines), moderate-to-vigorous physical activity moderated the association between waking hot flash rate and a vascular measure (flow-mediated dilation). The interaction was statistically significant (p=0.04), but physical activity did not independently predict vascular function, and the study does not show that exercise reduces hot flashes. E2 and FSH did not explain the vascular variance. This was cross-sectional and cannot establish causation (54).

Treatment Evidence

Neurokinin Receptor Antagonists — A New Non-Hormonal Class

Fezolinetantⓘ (FDA approved 2023):

In the DAYLIGHT trial (n=453, 16 countries) designed specifically for women unsuitable for hormone therapy, fezolinetant significantly reduced VMS frequency (LSMD -1.93, p<0.001), severity (-0.39, p<0.001), and sleep disturbance (-2.5, p<0.001), with improvements from week 1. Short-term side effects were comparable to placebo (65% vs 61%). However, a hepatotoxicity signal emerged after the trial: the FDA issued a black box warning in December 2024 requiring liver function testing before starting treatment and frequently during the first 9 months (47, 64).

Elinzanetantⓘ:

In the 52-week OASIS-3 phase 3 trial (n=628), elinzanetant reduced VMS frequency by 1.6 events per day more than placebo at week 12 (p<0.001), with 73.8% vs 47.0% reduction in frequency. By week 50, women on elinzanetant averaged 1.4 moderate-severe VMS per day compared to 3.5 on placebo. No hepatotoxic signal was found over 52 weeks. However, treatment-emergent adverse events and discontinuations were higher — any TEAE 70.0% vs 61.1%, discontinuation 12.5% vs 4.1%, somnolence about 4 times higher, and fatigue about twice as high. No endometrial hyperplasia or meaningful BMD changes were observed. Sleep and quality-of-life improvements were descriptive secondary outcomes — the study was not powered to confirm them (83).

A systematic review and meta-analysis of 5 elinzanetant RCTs (n=1,699) confirmed the efficacy signal but also confirmed higher discontinuation due to adverse events (RR 2.18, p=0.0002), headache (RR 2.19), somnolence (RR 2.96), and fatigue (RR 3.39). Serious adverse events were not significantly different. The SR/MA authors explicitly state that elinzanetant should not replace clinical assessment for hormone therapy eligibility (117).

Q-122 — A Distinct Mechanism (Not an NK Receptor Antagonist)

Q-122ⓘ (100 mg twice daily):

Behavioral and Digital Options

Self-administered clinical hypnosis showed a greater responder rate than sham (60.4% vs 42.2%, p=0.006) and a particularly strong signal in a breast cancer subgroup (n=62, p=0.002, η²p=0.16). However, the primary mixed-effects test in the full sample was borderline non-significant (p=0.06), and the effect was specifically on moderate hot flashes — mild, severe, and very severe categories were not significant (96).

A digital menopause app (Caria) reduced hot flash distress, depression, and sleep scores over 6 weeks — but hot flash frequency did not significantly change. The intervention affects how women experience VMS, not how often they occur. Anxiety improved similarly in both arms, sleep improvement was front-loaded (significant from baseline to 3 weeks but not from 3 to 6 weeks), and the sample was iOS-only, mostly White, and recruited through MTurk with education skew — so the finding is promising but not broadly generalizable (67).

Treatment Gaps

In a real-world study of 618 breast cancer survivors on endocrine therapy (US + 5 European countries), 15.2% of all VMS prescriptions were systemic hormone therapy — notable because systemic HT is generally considered higher-risk in many breast cancer survivor contexts, though the dataset did not distinguish ER status or prescribing rationale. About one-third (33.1%) of those with moderate-to-severe VMS had no current prescribed treatment. SSRI/SNRI monotherapy was the most common drug class, with a paroxetine-tamoxifen interaction concern identified. This was pre-NK-antagonist-era data (40).

Questions to Bring to Your Doctor

• "My hot flashes are [frequent/severe/both]. Given my medical history, what treatment options are appropriate — and what does the evidence say about each one?"
• "Sleep disruption is more bothersome to me than the hot flashes themselves. Does that change which treatments we should consider?"
• "I cannot use hormone therapy. What are the evidence-based non-hormonal options, and how do they compare?"
• "I've heard about fezolinetant/elinzanetant. What are the benefits and risks for someone in my situation, including the liver monitoring requirements?"
• "I had breast cancer. Are there treatments being studied specifically for VMS in breast cancer survivors?"

Skin, hair, oral, and vulvovaginal changes are part of the perimenopause and postmenopause experience — and they are commonly underrecognized. In one clinic survey, nearly half of women had self-managed skin symptoms without medical guidance before connecting them to the menopausal transition. The patient-facing value of this section is validation and recognition, not a treatment menu.

An important caveat about the numbers in this section: Much of the symptom-frequency data below comes from a single specialist menopause-clinic survey (58) of 50 women, 77% of whom were already on hormonal treatment, at a private clinic. These are recognition-within-a-selected-sample figures — they tell you these symptoms are commonly reported among women who seek specialist menopause care, not that they affect all menopausal women at these rates.

Skin

Hair

In the same survey, 82% reported at least one hair symptom — thinning in 54%, shedding in 44%. These are linked to estrogen decline and relative androgen dominance. Pattern hair-loss severity correlates with menopausal status in the cited literature.

A specific pattern — frontal fibrosing alopecia (FFA) — is a scarring-type hair loss with autoimmune features. In cited studies, FFA onset was postmenopausal in 93-100% of cases. The dermatology review treats this pattern as dermatology assessment territory rather than standard menopause care. Off-label oral hair-loss medications referenced in the review (minoxidil, spironolactone, finasteride/dutasteride) are not supported by menopause-specific evidence (113, 58).

Collagen Supplementation

Oral and Vulvovaginal Symptoms

In the same specialist clinic survey, 58% reported at least one oral symptom and 36% reported dry mouth. Vulval symptoms were even more common: 84% reported at least one, with dryness at 58%, itchiness at 54%, and soreness at 38%.

Oral symptoms are easy to lose in the menopause conversation. The evidence suggests that oral changes during perimenopause may benefit from dental or oral medicine assessment, but menopause-specific oral-symptom trials are limited. Vulvovaginal symptoms are addressed in detail in the Genitourinary Health section, where vaginal estrogen, DHEA, and ospemifene are discussed per ICSM 2024 guidance (58).

Body Image

Dry Eyes

Dry-eye symptoms are addressed in the What to Watch For section. In brief: 64.9% of midlife women in a Thai gynaecology/menopause clinic (n=262) had OSDI-defined dry-eye symptoms, with computer-based work as the only independent multivariate predictor of moderate-to-severe symptoms. HRT users were excluded from that study, and the broader literature on HRT and dry eye is inconsistent (82).

Questions to Bring to Your Doctor

• "I've noticed [skin/hair/oral/vulval] changes that started around the time my periods became irregular. Could these be related to perimenopause?"
• "I had a pre-existing skin condition that has gotten worse. Is that consistent with what the research shows during the transition?"
• "My hair is thinning in a pattern along my hairline. Is that the kind of pattern that the dermatology literature treats differently?"
• "I have dry mouth and oral changes. Is there guidance on whether this needs dental assessment during perimenopause?"

Genitourinary syndrome of menopause — the umbrella term for vaginal, urinary, and sexual changes caused by declining estrogen — is chronic and progressive. GSM does not resolve without treatment. Symptoms return approximately 1 month and signs approximately 3 months after discontinuing effective treatment (86).

The fair prevalence estimate is 40-60% of postmenopausal women, though reported ranges span 14-87% depending on the study. Vaginal dryness is reported at 47-100%, dyspareunia at 20-77.6%, and urinary incontinence at 23-50%. Age and time since menopause affect both presence and severity (86).

An important diagnostic note: GSM is a broader term than vulvovaginal atrophy (VVA), but it may reduce diagnostic specificity. Each GSM symptom can have multiple causes requiring differential diagnosis — urinary symptoms may reflect overactive bladder or pelvic floor dysfunction, not only estrogen decline (86).

The Scale of Undertreatment

Treatment Options — GSM Symptoms and Tissue Outcomes

GSM symptom-tissue outcomes (dryness, dyspareunia, maturation index, vaginal pH, visible VVA signs) and sexual-function outcomes (desire, arousal, frequency, global function scores, pain with sexual activity) have different evidence bases. The same therapy may improve one and not the other within the same population over the same follow-up period.

Local Vaginal Estrogen

Vaginal estrogenⓘ displays class-effect efficacy across formulations — estradiol tablets (4-10 mcg), softgel inserts, rings, and creams; estriol gels, creams, and inserts; and promestriene. At recommended doses, LET does not raise circulating estradiol above normal postmenopausal levels. Formulation choice is based on patient preference to support compliance. No routine progestogen is needed at recommended doses (86).

Vaginal DHEA

Vaginal DHEAⓘ significantly reduces dyspareunia and dryness after 12 weeks, with dual estrogenic-androgenic intracrine activity and without significantly increasing circulating sex steroids (86).

Ospemifene

Ospemifeneⓘ is now considered a first-line pharmacological option alongside LET, after 5-year VTE safety data showed reassuring results. It has a neutral-to-antagonist effect on breast tissue. Regulatory status differs: EMA permits it after completed breast cancer treatment; FDA considers it contraindicated (86).

Vaginal Laser

Vaginal laser therapyⓘ has not shown benefit over sham in controlled trials. Regulatory agencies and scientific societies do not support routine clinical use (86).

What the AHRQ/PCORI Systematic Review Shows

For Breast Cancer Survivors

GSM affects up to 70% of breast cancer survivors per ICSM estimates. Women on aromatase inhibitors are more symptomatic than those on tamoxifen (vaginal dryness 57.6% vs 32.4% vs 1.8% in controls). The treatment approach in this population follows a different path: non-hormonal options first, then low or ultra-low-dose local estrogen only after risk-benefit discussion with an oncologist. See the Breast Cancer & HRT section for the full risk framing on vaginal estrogen safety after breast cancer, including recurrence caution for aromatase-inhibitor users (86, 88).

Emerging and Uncertain Options

Soy isoflavones showed a postmenopausal vaginal-dryness signal (SMD -1.88) in a systematic review of 13 trials, but with considerable heterogeneity (I²=97%). A urogenital-symptom improvement was cleaner (SMD -0.33, I²=0%). Dyspareunia and VMS were not statistically significant. The evidence supports a possible dryness/urogenital benefit — not global sexual function or VMS. Women with estrogen-sensitive cancers or on anti-estrogen medication should discuss soy supplementation with their clinician (127, 77).

Probiotics showed large pooled effects for vaginal dryness (SMD -0.95), Nugent score (SMD -0.91), and VMS (SMD -0.96) in a meta-analysis of 7 RCTs, all with I²=0%. Sexual symptoms and somatic symptoms were not significant. However, 41% of included studies had high or critical risk of bias, the systematic review was sponsored by Health & Her (which participated in design, execution, analysis, and interpretation), and 5 of 7 underlying estriol-combination studies were commissioned by the product developer (Medinova/Gynoflor). These are emerging signals requiring substantial confidence discounting (73).

Abnormal Uterine Bleeding — Cross-Reference

Abnormal uterine bleeding during perimenopause is covered in the What to Watch For section (S5), including the distinction between physiologic and red-flag bleeding, AUB process-of-care disparities in US emergency departments, and the association between AUB and comorbid anxiety/depression. If you are experiencing irregular or heavy bleeding, see that section for the evidence on when evaluation is warranted and how care-access patterns differ by race, age, and geography.

Sexual Function — A Separate Evidence Lane

Sexual-function outcomes have a different and generally weaker evidence base than GSM tissue outcomes.

A Cochrane review (36 RCTs, 23,299 women) found that estrogen alone may modestly improve composite sexual-function scores in symptomatic or early postmenopausal women (SMD 0.50, 95% CI 0.04-0.96, 3 studies, n=699, moderate quality). In unselected postmenopausal women, the confidence interval crossed zero. The pooled estrogen-alone effect was significant but with very high heterogeneity (I²=92%). Only 1 of 36 trials evaluated perimenopausal women. None enrolled only women with sexual dysfunction. Only 7 studied sexual function as the primary outcome (22).

In the MsFLASH trial (n=302, mean age 61), vaginal estrogen tabletⓘ did not significantly improve sexual activity frequency or pain severity compared to placebo. However, the parent trial reported that 80% of the estradiol arm versus 65% of the placebo arm experienced "meaningful benefit" (p=0.02) — a quality-of-life signal not explained by more frequent sex or less pain (5).

In a head-to-head trial (n=172), DHEA was significantly superior to vaginal estradiol for dyspareunia in the severe-dyspareunia subgroup (OR 3.4, 95% CI 1.07-10.5), but the overall comparison was near-threshold and not conventionally significant (OR 2.87, p=0.051). Estradiol was superior for objective VVA signs — friability, petechiae, pH, and maturation index (all p<0.001). The trial illustrates why symptom endpoint matters: DHEA favored severe dyspareunia, while estradiol favored objective VVA signs (121).

Sexuality Is Not a Homogeneous Experience

A qualitative meta-synthesis across 21 studies in 13 countries (610 women) found that sexuality during menopause is shaped by relationship dynamics, sexual autonomy, personal history, and cultural context — not by biology alone. Seven themes emerged: fertility/femininity/desirability; performative sex as duty in patriarchal or religious contexts; menopause as sexual freedom; rather no sex than bad sex; partner communication as the central theme; privilege (money, knowledge, autonomy) differentiating outcomes; and the need for knowledge, willingness, and access in any support system (85).

Where communication exists, couples adapt — lubricants, positions, non-penetrative sex, more time. Where communication is absent, sex becomes "sorrow or conflict." A vicious circle can develop: painful sex leads to decreased desire, then avoidance, then worse relationship dynamics. Women with a prior positive view of sex tend to seek solutions; those with prior negative experiences are more likely to give up.

Some women experience menopause as sexual liberation — freedom from menstruation, contraception, and pregnancy worry. Some report better sex with age through confidence, experience, and self-knowledge. Neither patients nor healthcare providers typically initiate conversations about sexual health during menopause — a "two-way taboo" (85).

Urinary Health

Urinary incontinence affects an estimated 45-50% of menopausal women. There is no sharp prevalence jump at menopause itself — age, BMI, parity, and prior urinary incontinence during pregnancy are all heavily influential. Stress urinary incontinence tends to predominate before and early after menopause, while urgency and mixed incontinence become more common with age and time since menopause. BMI is a major modifiable risk factor: each 5 kg/m² increase raises UI risk by approximately 20% (overweight OR 1.27, obese OR 1.60, BMI ≥35 OR 1.85) (97).

A critical distinction for treatment: systemic estrogen is associated with increased urinary incontinence risk in postmenopausal women, while vaginal estrogenⓘ does not share this signal and may improve UI symptoms when UI coexists with GSM (97). Per ICS guidance summarized in the review, pelvic floor muscle training is positioned as the first step, with PFMT plus intravaginal estriol showing better results than estriol alone in cited studies.

UTI Prevention

Questions to Bring to Your Doctor

• "I have vaginal dryness and pain with sex. Which treatment — local estrogen, DHEA, or ospemifene — makes the most sense given my medical history?"
• "I'm getting more UTIs since menopause. Is there evidence for vaginal estrogen to prevent them?"
• "I have urinary incontinence. Should I be using local vaginal estrogen, pelvic floor therapy, or both — and does systemic hormone therapy carry a different risk for bladder symptoms?"
• "Sex has changed for me during menopause. Is this a tissue problem, a relationship dynamic, or both — and what does the evidence say about treatment for each?"
• "I had breast cancer. The FDA and EMA disagree about ospemifene. What does my oncologist recommend for my specific situation?"

The menopausal transition is not just a symptom phase — it is a period when cardiovascular, metabolic, and bone health trajectories shift. Understanding these shifts matters because risk factors and treatment decisions discussed during the transition may shape health over the next 10-20 years.

Cardiovascular Risk Follows Three Timing Layers

Cardiovascular risk during and after menopause is best understood as three distinct timing layers — not collapsed into "menopause causes heart disease."

Layer 1 — Lipid and lipoprotein burden shifts during perimenopause. In the SWAN cohort, LDL-C, ApoB, and total LDL particle counts all increased significantly during the perimenopause stage. ApoB and total LDL-P were independently associated with subclinical atherosclerosis measures (carotid intima-media thickness, coronary artery calcium). These are surrogate endpoints — they measure artery-wall changes, not heart attacks or strokes (25).

Layer 2 — Palpitations co-occur with the transition but are not independently linked to subclinical cardiovascular disease. About half of women experience moderate-to-high palpitations during perimenopause and early postmenopause (trajectories: sustained low 49.8%, moderate 34.3%, high 15.9%). In fully adjusted SWAN models, palpitation trajectories were not associated with subclinical CVD markers after accounting for BMI, blood pressure, glucose, and sleep (13). Chest pain, syncope, or persistent new arrhythmia fall outside this reassuring pattern and are appropriately evaluated in a clinical setting.

Layer 3 — Aortic stiffness acceleration is a late-postmenopause phenomenon. Significant carotid-femoral pulse wave velocity acceleration (0.122 m/s per year, p<0.001) emerged in late postmenopause (8 or more years after the final menstrual period) — not during the transition itself. The clinical implication: the risk-factor deterioration that happens around the transition (lipids, adiposity, blood pressure) is what later contributes to measured arterial changes (30).

CVD is the leading cause of death in women worldwide — causing approximately 10 times more deaths than breast cancer in the US. At the same time, guideline consensus is clear that estrogen is not recommended solely for primary cardiovascular prevention despite favorable effects on some risk factors (53).

Hormone Therapy and Cardiovascular Risk — Formulation, Route, and Endpoint All Matter

"Is hormone therapy safe for my heart?" does not have a single answer. The evidence shows that formulation, route, regimen, and the specific cardiovascular outcome measured all change the picture.

A Korean nationwide cohort found adjusted higher composite CVD risk for tibolone (HR 1.14), oral estrogen (HR 1.25), and transdermal estrogen (HR 1.29) — though crude event incidence was actually lower among HT users (5.5% vs 7.4%), with the adjusted risk emerging only after accounting for confounding (36). The Swedish and Korean studies do not fully agree on transdermal-estrogen cardiovascular risk — this is cross-study heterogeneity, not a settled answer.

Route Selection Across Comorbidity Axes

When a woman carries multiple conditions that affect route choice, the decision involves balancing competing considerations rather than following a single rule:

• Dyslipidemia axis: Estrogen pillsⓘ produce stronger LDL/Lp(a) reductions and HDL increases, but may raise triglycerides. Per an EMAS clinical guide, an estrogen patchⓘ is preferred when hypertriglyceridemia is present. Lp(a) reduction with MHT was 20.4%, with oral producing a 37.7% greater relative reduction than transdermal (8). MHT is not a first-line therapy for dyslipidemia or cardiovascular risk reduction — statins remain the mainstay.

• Type 2 diabetes / glucose axis: Estrogen pill (estradiol)ⓘ showed advantages for glucose metabolism in women with T2D at low cardiovascular risk. Transdermal is preferred when moderate-to-high cardiovascular risk or obesity dominates. This is the opposite direction from the general cardiovascular route preference (33).

• Vascular / migraine / VTE axis: Reviewed guidance generally favors low-dose transdermal estrogen for women with migraine (especially with aura), hypertension, BMI ≥30, or prior VTE/stroke risk.

Across all three axes, in the reviewed evidence, micronized progesterone and dydrogesterone tend to have lower-risk profiles (neutral on lipids, neutral on glucose, lower breast-cancer and meningioma signals than several synthetic progestins in the cited studies). This framework is a balancing tool, not a hierarchy — clinicians weigh which comorbidity dominates the individual patient's risk profile.

Metabolic Health

Body composition and lipid parameters worsen during perimenopause but stabilize after menopause, shifting to a slower age-related trajectory (53). In the US, 74.2% of midlife women were overweight or obese in 2021 (up from 49.2% in 1990), with projections reaching 83.4% by 2050. The increase is driven by a shift into the obesity-range BMI category, not simply stable overweight prevalence (119).

Lean and muscle mass decline across the transition. SWAN longitudinal data show the annual rate of lean-mass decline accelerates during the transition (-0.68% per year) compared to pre-FMP years (-0.17%) and stabilizes afterward (+0.02%). Most evidence uses DXA, which overestimates muscle mass compared to direct measures like MRI or CT. The human evidence linking estradiol decline specifically to muscle protein breakdown remains speculative — it is supported by animal and cell models only. Resistance exercise remains the practical intervention with evidence that postmenopausal women still gain lean mass with training despite potentially blunted responses (115).

Hormone therapy is not established for sarcopenia prevention. A systematic review of 43 studies found no consistent benefit, and critically, only 1 of 15 included RCTs used micronized progesterone — the rest used older, more androgenic progestins. Modern regimens (transdermal estradiol plus micronized progesterone) are essentially unstudied for this outcome (68).

Bone Health

[EVIDENCE] In the first two years after the final menstrual period, women lose approximately 2.5% of lumbar spine bone density per year and 1.8% of femoral neck density per year (SWAN longitudinal data). Hormone therapy reduces fracture risk regardless of fall risk or baseline FRAX score. Both oral and transdermal routes provide similar skeletal benefits, with some evidence that estradiol may be slightly more effective than conjugated equine estrogen. Benefits persist during therapy and may continue after stopping. Non-hormonal VMS treatments do not provide bone protection. (PMID 39928407, ref 53)

Emerging screening research suggests site-specific predictors: FSH independently predicts lumbar spine BMD (β=-0.072, p=0.009), while estradiol predicts femoral neck BMD (β=0.138, p=0.020) — different hormones, different bones. A combined β-CTX and low-estradiol screening approach achieved an AUC of 0.950 for identifying high-risk perimenopausal women (100, 103). Both thresholds are observed and not yet prospectively validated.

Elinzanetant showed no clinically meaningful BMD or bone-turnover changes versus placebo over 52 weeks in OASIS-3 — an elinzanetant-specific finding that does not generalize to the whole NK antagonist class or to longer-term use (83).

If You Have Premature Ovarian Insufficiency or Early Menopause

POI and early menopause carry distinct long-term cardiovascular and metabolic risk patterns — including a 50% increased risk of type 2 diabetes and premature mortality driven largely by CVD from estrogen deficiency. Asian women may face disproportionately higher cardiovascular risk at lower BMI. These patterns and their management are covered in the Special Populations section (60).

Questions to Bring to Your Doctor

• "Given my lipid profile, blood pressure, and family history, what does the cardiovascular evidence say about hormone therapy route and formulation for someone like me?"
• "I have type 2 diabetes. Does that change which route of hormone therapy makes sense — and does the evidence point in a different direction than for cardiovascular risk?"
• "I'm concerned about bone loss but I don't have symptoms. Is there evidence for starting hormone therapy specifically for bone protection in my situation?"
• "I've been having palpitations. The SWAN data are reassuring, but I also have [specific symptom]. Should we investigate further?"
• "How do I know if my muscle and body composition changes are menopause-related or age-related — and does the distinction matter for what I should do?"

This is one of the most emotionally charged questions about hormone therapy. The evidence answers it with formulation-specific, endpoint-specific, and population-specific precision — which means the answer is not a simple yes or no.

Four Distinct Questions, Four Different Answers

The breast cancer and hormone therapy literature uses overlapping language for what are actually four distinct questions. Blending them leads to confusion.

1. Breast cancer incidence — Among women who do not have cancer, who develops it? This is what most studies measure. Combined estrogen-plus-progestogen therapy carries the clearest and most consistent signal for increased incidence. Estrogen-only therapy and tibolone vary more by trial, dataset, duration, and population.

2. Breast cancer-specific mortality in the full initially cancer-free cohort — Among all women who started hormone therapy, how many die from breast cancer? This is a different question with a different answer. In the NOWAC Norwegian prospective cohort, current estrogen-plus-progestogen therapy was associated with doubled luminal A-like breast cancer mortality (HR 2.15). In the WHI trial, oral conjugated estrogen alone in hysterectomized women was associated with reduced breast cancer mortality (HR 0.60) (45, 10).

3. Survival among diagnosed breast cancer patients — Of women who develop breast cancer, how many survive 5 or 10 years? This is where observational data consistently show that pre-diagnostic hormone therapy users look "better." But this signal is affected by multiple biases: collider/index-event bias, healthy-user bias, screening and detection bias (HT users get more mammograms and are diagnosed at earlier stages), and tumor-subtype favorability (HT-associated cancers tend to be lower-grade with better baseline prognosis). These survival findings do not support the conclusion that hormone therapy improves breast cancer survival or is safe after diagnosis.

4. All-cause mortality — The ultimate net-effect outcome. In the WHI 18-year follow-up (n=27,347, over 98% mortality capture), neither combination hormone pillⓘ nor estrogen pill aloneⓘ significantly changed all-cause mortality (pooled HR 0.99). Hormone therapy changes which outcomes are affected, not the total (2).

What the Largest Studies Show

WHI — Estrogen Alone in Hysterectomized Women

WHI — Estrogen Plus Progestogen

In the same WHI program, CEE plus medroxyprogesterone acetate in women with intact uterus increased breast cancer incidence (HR 1.28, 95% CI 1.13-1.45). The increase became significant at year 6 and persisted at least a decade after stopping. Breast cancer mortality trended higher but was not statistically significant (HR 1.35, 95% CI 0.94-1.95) (10).

Finnish Nationwide Cohort

If You Are a Breast Cancer Survivor

The evidence above describes hormone therapy risk in women who have not had cancer. If you have a breast cancer history, the decision environment is different.

The unmet need is real. In a community survey of breast cancer survivors 6 years after diagnosis (n=385), 90% reported VMS or sleep disturbance, 75% vaginal dryness, 62% mood swings, and 59% sexual difficulties. Less than one-third were offered treatment, and less than half of those treated found it effective (35).

The Hickey Lancet 2024 cancer-survivor framework frames systemic MHT as generally not recommended after breast cancer, especially ER-positive disease, with careful exceptions considered only when quality of life is substantially affected and disease risk is low, through shared decision-making with the oncology team. The framework is cancer-type-specific, age-specific, and route-specific — transdermal MHT is preferred over oral in cancer patients due to elevated VTE risk (35).

The strongest post-BC systemic MHT evidence comes from two terminated RCTs that disagree. The HABITS trial (synthetic progestinⓘ-based regimens) was terminated early after finding a 3.5-fold increased risk of new breast cancer events with MHT (26/174 MHT vs 7/171 control, adjusted HR 3.5). The Stockholm trial (synthetic progestinⓘ-based regimens) found no increased recurrence risk (HR 0.82). The discrepancy is likely explained by lower-risk patients in Stockholm (16% vs 26% node-positive), more tamoxifen use (52% vs 21%), a different progestin, and lower progestin exposure (88). The conflict between these two trials is why post-diagnosis systemic MHT is a fundamentally different decision from population-level MHT risk assessment.

Vaginal estrogen after breast cancer has growing safety evidence. A meta-analysis of 8 observational studies found no increased recurrence, breast-cancer-specific mortality, or overall mortality with vaginal estrogen after breast cancer (follow-up up to 15.2 years) (88). Separately, a 2024 UK registry study of 49,237 breast cancer patients aged 40-79 found no evidence of increased breast cancer mortality with vaginal estrogen use. However, a 2022 Danish data linkage study found a small increase in recurrence among patients on adjuvant aromatase inhibitors using vaginal estrogen, with no worse survival. These two findings sit together: mortality reassurance does not mean no recurrence concern in every subgroup, particularly for AI users. Ultra-low doses minimize systemic absorption (35).

Systemic estrogen plus aromatase inhibitor is counterproductive — the cited expert panel reached 100% agreement on this point (88).

Post-cancer GSM treatment evidence is mostly limited or uncertain. Vaginal prasterone showed no benefit versus vaginal moisturizer in one RCT (n=464). Vaginal CO2 laser showed no benefit over sham in two controlled trials. Ospemifene's regulatory status after breast cancer differs by jurisdiction: the EMA permits it after completed breast cancer treatment, while the FDA considers it contraindicated (not adequately studied in breast cancer populations). Efficacy and safety specifically after cancer remain uncertain in the published evidence. CBT improved sexual function, desire, arousal, lubrication, and reduced distress in one RCT — among the strongest non-hormonal signals for this population (35).

Body-identical progesterone has not been shown to increase breast cancer risk for up to 5 years in observational data (MISSION RR 0.91). Beyond 5 years, the E3N cohort found elevated risk (HR 1.31), but could not distinguish progesterone from dydrogesterone and 57% of participants also used synthetic progestin (88). At the tissue level, a short prospective trial (n=77, 2 months) found that body-identical estradiol with natural progesteroneⓘ did not increase Ki-67, bcl-2, or mammographic density, while CEE plus MPA did — marker evidence, not incidence evidence (88).

LNG-IUS carries a small increased breast cancer risk in the general population — 14 additional cases per 10,000 women over 0-5 years — while reducing ovarian and endometrial cancer risk. Data in breast cancer survivors are insufficient (88).

Testosterone patch/gelⓘ shows an observational signal of lower breast cancer risk (RR 0.48, 0.37-0.62), with androgen receptor agonists antagonizing estrogen-stimulated tumor growth in preclinical work. Long-term safety data in breast cancer survivors do not exist (88).

Questions to Bring to Your Doctor

• "I am considering hormone therapy. Given the evidence on formulation and duration, what does my specific risk look like — and how does it compare to the symptom burden I am experiencing?"
• "I had [ER+/ER-/DCIS] breast cancer. What does the current evidence say about hormone therapy options and risks for my specific subtype?" (See also the Making Your Decision section.)
• "I am a breast cancer survivor with persistent vaginal symptoms. What are the evidence-based options, including what has and has not worked in trials?"
• "I've heard that newer or body-identical formulations eliminate the breast cancer risk. What does the Finnish data actually show about that?"
• "What is the difference between breast cancer incidence risk and survival after diagnosis — and why does it matter for how I interpret the evidence?"

Every woman's menopause is shaped by her body, her medical history, her culture, and her healthcare system. This section addresses the populations for whom general menopause guidance must be modified — and the global contexts where access to care is itself a barrier.

Premature Ovarian Insufficiency

If your ovaries stopped functioning before age 40, or if you experienced early menopause between ages 40 and 45, the management approach is fundamentally different from standard menopause care.

ADHD and Perimenopause

ADHD is frequently underdiagnosed in women, and hormonal changes during perimenopause can exacerbate or unmask symptoms. The overlap between ADHD and perimenopause symptoms — brain fog, concentration difficulty, mood swings, emotional dysregulation — is substantial. The key distinction is timing: ADHD symptoms are typically present from childhood, while perimenopause-linked symptoms emerge in midlife (125).

Emerging, sample-specific evidence suggests women with ADHD may have elevated vulnerability to hormone-related mood symptoms and cardiometabolic risk during perimenopause — but these signals come from clinically diagnosed cohorts, self-reported advocacy-platform surveys, and specialty-clinic samples rather than population-prevalence estimates. Expert consensus — without supporting RCTs — discusses adding hormone therapy rather than adjusting stimulant medication first when perimenopause symptoms persist, and notes that progesterone may antagonize dopamine signaling, which is relevant to progestogen choice (125, 74).

Endometriosis

Endometriosis can persist or develop after menopause (postmenopausal prevalence 2-5%) and may itself cause premature or early menopause. In a pooled meta-analysis of 279,948 women across 5 international cohorts, endometriosis was associated with a 7.5-fold higher rate of surgical menopause (HR 7.54), surgical menopause occurring 1.6 years earlier on average, and an OR of 1.36 for spontaneous POI (81).

The EMAS clinical guide frames management differently from standard menopause care: continuous combined estrogen-progestogen therapy is preferred, and estrogen-only therapy is avoided even after hysterectomy — a counter-intuitive exception to standard guidance, because unopposed systemic estrogen is the primary concern for recurrence and malignant transformation. Ovarian cancer absolute lifetime risk increases from 1.3 to 2.5 per 100 women with endometriosis; deep infiltrating endometriosis with endometriomas carries substantially higher risk (81).

Type 1 Diabetes

T1D adds a distinct metabolic layer to the menopause experience. In a Dutch survey of 159 T1D women, 67.4% reported moderate-to-severe glucose-regulation changes after their final menstrual period — but the direction was heterogeneous, not unidirectional: 41.9% reported higher glucose, 19.6% lower, and 38.5% no change. Both hyperglycemic and hypoglycemic events increased. This was patient-perceived change, not objective CGM/HbA1c data (79).

Disease-specific evidence for HRT in T1D is sparse — only one underpowered trial exists, with no T1D-specific bone, cardiovascular, or sexual-function RCTs. Lipid response to HRT may be blunted in diabetes. VMS and hypoglycemia symptoms can mimic each other, creating real patient burden. The accurate framing is: general-population evidence suggests possible HRT benefits, but T1D-specific evidence is sparse and underpowered, warranting individualized assessment with transdermal estradiol generally considered when HRT is used (101).

Migraine

Migraine patterns shift during the menopausal transition. Migraine without aura often improves after menopause. Migraine with aura tends to persist and independently increases ischemic stroke and other vascular-event risk. In the NOWAC Norwegian cohort (n=4,825), mean migraine cessation age was 49.7 — close to mean menopause age of 50.1 — but 46.3% continued migraines postmenopause and nearly 1 in 5 still experienced them after age 60. 9.2% reported migraine onset after age 50 (70).

Reviewed guidance generally favors low-dose estrogen patchⓘ for women with migraine, especially migraine with aura. Oral contraceptives containing estrogen are contraindicated for migraine with aura. Continuous progestogen regimens may reduce withdrawal-related migraine attacks, but this is a progestogen-class statement — the cited micronized-progesterone review found no data on MP's effect on migraine specifically (122, 39). CGRP monoclonal antibodies, gepants, and ditans are effective non-vasoconstrictive alternatives for women with cardiovascular contraindications.

Surgical Menopause

BRCA Carriers After Risk-Reducing Surgery

In the largest prospective controlled cohort of BRCA1/2 carriers undergoing risk-reducing salpingo-oophorectomy (WHAM, 104 RRSO + 102 comparators, 24-month follow-up), VMS peaked at 3 months and did not worsen through 24 months. Non-HRT users experienced severe bone loss (lumbar spine -7.8%, total hip -5.2%, femoral neck -6.0%), while HRT users showed substantially mitigated loss (lumbar spine -2.3%, total hip +0.5%). HRT did not prevent or treat depression or anxiety — the authors are explicit on this point (75). In a separate prospective study of 43 BRCA carriers undergoing RRSO (48), sexual function declined significantly, with 66.7% meeting criteria for sexual dysfunction versus 25.4% of controls at 1 year. Testosterone and free androgen index did not correlate with sexual function scores, counter to the common reasoning.

For breast-cancer risk and prior-BC contexts in BRCA carriers, see the Breast Cancer & HRT section — the RRSO-specific MHT guidance here does not replace that section's regimen/endpoint analysis.

Postmenopausal Ovary Removal at Benign Hysterectomy

In a British Columbia population-based cohort (n=18,676 women aged 50-60 at hysterectomy), bilateral salpingo-oophorectomy at benign hysterectomy did not increase hard cardiovascular events or fractures. However, it increased CVD-predisposing conditions (diabetes aHR 1.36, hypertension aHR 1.10) and doubled HRT initiation (aHR 2.04). Postmenopausal ovaries continue producing androgens that are converted to estrogens — BSO eliminates this residual hormonal contribution (123).

Cultural Diversity Shapes the Menopause Experience

Menopausal biology and needs occur globally. Both evidence quality and access to care differ by population and setting.

The evidence base itself is uneven. A scoping review of 252 studies across 41 low- and middle-income countries found that VMS, joint pain, and sexual concerns appear at rates comparable to high-income countries — but severity and burden data are scarce. Only 4% of studies were nationally representative, only 17.5% used STRAW+10 or WHO menopause criteria, and 85% were cross-sectional. National-level age-at-menopause data are lacking (69).

Provider-initiated conversations are largely absent across cultures. Among 334 African American women, 0% reported their healthcare provider proactively asking about menopause. Mean symptom onset was age 41.5, and 81% reported symptoms lasting 9 or more years. 89% used prayer as a primary coping strategy and 67% used no prescription medications. Among immigrant Muslim women in the UK (n=12), participants reported GP refusal of HRT, limited knowledge about options, and dismissive encounters — but women who did access HRT reported "life-changing benefits." In Nigeria, women frame menopause as requiring endurance rather than care. In Oman, menopause symptoms have culturally specific names — "harara dakhiliya" (internal heat), "kalam mamnoua" (forbidden words) — and CBT was completely absent from all clinical narratives (110, 55, 114, 118).

Access and affordability are structural barriers. Across 6 LMICs studied by the MARIE consortium, HRT formulary availability ranged from 3 of 20 medicines listed (Nepal) to 18 of 20 (Brazil). Availability does not equal affordability: in Nigeria, one combined HRT product cost 260 minimum-wage days for a 2-month supply — 221.52% of annual GNI per capita. BMS guidelines were authored for resource-rich, predominantly Caucasian populations and do not adequately address LMIC realities (128).

South Asian American women in a metro-area cohort (MASALA, n=405) recalled natural menopause at mean age 48 / median 49 — though the authors flag these figures as likely affected by recall bias. 12% reported bothersome hot flashes persisting more than 20 years after menopause. 80% were overweight or obese using Asian-specific BMI cutoffs. The cohort was predominantly Indian-born (82%) and college-educated (88%) — not representative of all South Asian women (59).

Chronic psychosocial stress reframes "culture" as life-course exposure. A US scoping review mapped four stressor domains linked to menopausal experience: socioeconomic position, intimate partner violence and sexual assault/PTSD, childhood abuse and neglect, and racialized stress. The review used intersectionality and life-course frameworks rather than treating menopause as a discrete biological event. Southern US populations — particularly Gulf South low-income and racialized communities — were underrepresented despite high relevance. This was a mapping exercise, not a meta-analysis (41).

What women are looking for online. In a UK survey (n=627), 92.7% used the internet for menopause information, 84.2% as their first source, and 24.4% used the internet only. NHS websites and charities were the most trusted sources; social media was widely used but not trusted. Women with surgical menopause were more likely to search for lubricants, osteoporosis information, and surgical-menopause-specific content — and 23% used a secondary source because online information was missing. 62% of late-perimenopausal women wanted verification of what they found online. The most commonly requested content included comprehensive symptom lists (including atypical symptoms like dental changes, dry eyes, and itchy ears), HRT decision-support tools, treatment alternatives, comorbidity interactions, workplace and family information, and lived-experience narratives (89).

If you cannot use hormone therapy, the evidence shows high symptom burden and low satisfaction with available alternatives (2.0 out of 5 for non-hormonal options versus 3.7 for HT in a qualitative study of 32 HT-unsuitable women, all with moderate-to-severe VMS). Evidence-based non-hormonal options — including CBT-I for insomnia, exercise at specific doses for mood, neurokinin receptor antagonists for hot flashes, and self-administered hypnosis — are covered in the Treatment Options and Vasomotor Symptoms sections (78).

Culturally responsive menopause care requires both communication adaptation and material access. Education alone is insufficient when HRT formulations, trained clinicians, interpretation services, insurance coverage, or affordable supply chains are missing.

Questions to Bring to Your Doctor

• "I have [POI/ADHD/endometriosis/T1D/migraine/surgical menopause]. Does that change the standard menopause approach for me — and how?"
• "I had risk-reducing surgery for a BRCA mutation. What does the WHAM study say about bone protection and hormone therapy for someone in my situation?"
• "My cultural background or faith shapes how I think about menopause treatment. Can we discuss options that work within my values?"
• "I've been managing symptoms on my own because no one asked about menopause. Can we start that conversation now?"
• "Are there treatment options I should know about that aren't available in my country or covered by my insurance?"